

Special Issue

Advances in the Immunotherapy of Metastatic Cancer

Message from the Guest Editor

Metastatic cancer remains a difficult challenge in oncology, with traditional therapies often providing poor prognoses and very limited long-term benefits. However, the emergence of immunotherapy has radically transformed the management of metastatic cancers. Beyond ICIs, novel approaches such as adoptive cell therapies (CAR-T, TCR-T, and TIL therapies), cancer vaccines, oncolytic viruses, and bispecific antibodies are expanding the therapeutic armamentarium. Additionally, combination strategies integrating immunotherapy with chemotherapy, radiotherapy, or targeted agents are being actively explored to enhance efficacy and offer new hope for patients with advanced disease. Despite these successes, significant challenges remain. This Special Issue explores the latest advancements in immunotherapy for metastatic cancer, covering mechanistic insights, preclinical and clinical studies, biomarker discovery, and emerging resistance mechanisms.

Guest Editor

Dr. Gianluca Tomasello

Oncology Division, ASST Ospedale Maggiore di Crema, Largo U. Dossena 2, 26013 Crema, CR, Italy

Deadline for manuscript submissions

5 June 2026



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/243809

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)